Mouse Monoclonal FTO antibody. Suitable for Flow Cyt, WB, ICC/IF and reacts with Human, Rat samples. Cited in 51 publications. Immunogen corresponding to Synthetic Peptide within Human FTO conjugated to Keyhole Limpet Haemocyanin.
Constituents: 50% Glycerol (glycerin, glycerine), 0.87% Sodium chloride, 0.238% HEPES, 0.01% BSA
Flow Cyt | WB | ICC/IF | |
---|---|---|---|
Human | Tested | Tested | Expected |
Rat | Expected | Tested | Tested |
Cow | Predicted | Predicted | Predicted |
Dog | Predicted | Predicted | Predicted |
Horse | Predicted | Predicted | Predicted |
Primates | Predicted | Predicted | Predicted |
Sheep | Predicted | Predicted | Predicted |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info 1 µg for 106 Cells | Notes ab170191 - Mouse monoclonal IgG2a, is suitable for use as an isotype control with this antibody. |
Species | Dilution info | Notes |
---|---|---|
Species Rat | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Sheep, Horse, Cow, Dog, Primates | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Rat | Dilution info 1/1000 | Notes - |
Species Human | Dilution info 1/1000 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Sheep, Horse, Cow, Dog, Primates | Dilution info - | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Rat | Dilution info 1/100 | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Human | Dilution info Use at an assay dependent concentration. | Notes - |
Species | Dilution info | Notes |
---|---|---|
Species Sheep, Horse, Cow, Dog, Primates | Dilution info - | Notes - |
Select an associated product type
RNA demethylase that mediates oxidative demethylation of different RNA species, such as mRNAs, tRNAs and snRNAs, and acts as a regulator of fat mass, adipogenesis and energy homeostasis (PubMed:22002720, PubMed:25452335, PubMed:26457839, PubMed:26458103, PubMed:28002401, PubMed:30197295). Specifically demethylates N(6)-methyladenosine (m6A) RNA, the most prevalent internal modification of messenger RNA (mRNA) in higher eukaryotes (PubMed:22002720, PubMed:25452335, PubMed:26457839, PubMed:26458103, PubMed:30197295). M6A demethylation by FTO affects mRNA expression and stability (PubMed:30197295). Also able to demethylate m6A in U6 small nuclear RNA (snRNA) (PubMed:30197295). Mediates demethylation of N(6),2'-O-dimethyladenosine cap (m6A(m)), by demethylating the N(6)-methyladenosine at the second transcribed position of mRNAs and U6 snRNA (PubMed:28002401, PubMed:30197295). Demethylation of m6A(m) in the 5'-cap by FTO affects mRNA stability by promoting susceptibility to decapping (PubMed:28002401). Also acts as a tRNA demethylase by removing N(1)-methyladenine from various tRNAs (PubMed:30197295). Has no activity towards 1-methylguanine (PubMed:20376003). Has no detectable activity towards double-stranded DNA (PubMed:20376003). Also able to repair alkylated DNA and RNA by oxidative demethylation: demethylates single-stranded RNA containing 3-methyluracil, single-stranded DNA containing 3-methylthymine and has low demethylase activity towards single-stranded DNA containing 1-methyladenine or 3-methylcytosine (PubMed:18775698, PubMed:20376003). Ability to repair alkylated DNA and RNA is however unsure in vivo (PubMed:18775698, PubMed:20376003). Involved in the regulation of fat mass, adipogenesis and body weight, thereby contributing to the regulation of body size and body fat accumulation (PubMed:18775698, PubMed:20376003). Involved in the regulation of thermogenesis and the control of adipocyte differentiation into brown or white fat cells (PubMed:26287746). Regulates activity of the dopaminergic midbrain circuitry via its ability to demethylate m6A in mRNAs (By similarity). Plays an oncogenic role in a number of acute myeloid leukemias by enhancing leukemic oncogene-mediated cell transformation: acts by mediating m6A demethylation of target transcripts such as MYC, CEBPA, ASB2 and RARA, leading to promote their expression (PubMed:28017614, PubMed:29249359).
KIAA1752, FTO, Alpha-ketoglutarate-dependent dioxygenase FTO, Fat mass and obesity-associated protein, U6 small nuclear RNA (2'-O-methyladenosine-N(6)-)-demethylase FTO, U6 small nuclear RNA N(6)-methyladenosine-demethylase FTO, mRNA (2'-O-methyladenosine-N(6)-)-demethylase FTO, mRNA N(6)-methyladenosine demethylase FTO, tRNA N1-methyl adenine demethylase FTO, m6A(m)-demethylase FTO
Mouse Monoclonal FTO antibody. Suitable for Flow Cyt, WB, ICC/IF and reacts with Human, Rat samples. Cited in 51 publications. Immunogen corresponding to Synthetic Peptide within Human FTO conjugated to Keyhole Limpet Haemocyanin.
Constituents: 50% Glycerol (glycerin, glycerine), 0.87% Sodium chloride, 0.238% HEPES, 0.01% BSA
Protein G purified culture supernatant.
The FTO protein also referred to as Alpha-Ketoglutarate-Dependent Dioxygenase or Fat Mass and Obesity-Associated protein functions as an enzyme involved in demethylating nucleic acids specifically N6-methyladenosine (m6A) in RNA. This process impacts RNA stability and translation. FTO has a molecular weight of approximately 58 kDa. Higher expression levels of FTO are found in the brain including the hypothalamus which is an area known for regulating energy balance and appetite.
FTO influences energy homeostasis and adipogenesis. It acts as an important player in metabolic regulation and gene expression by modulating the m6A RNA modification. While FTO operates largely on its own its demethylation activity may interact with other RNA binding proteins that recognize m6A-modified RNAs integrating it into larger regulatory frameworks for RNA metabolism and cellular responses.
FTO is an important component in the regulation of energy balance and metabolism. The protein is closely associated with the mTOR signaling pathway which is essential for controlling cell growth proliferation and survival in response to nutrient availability. FTO also interacts with the leptin signaling pathway relating to its role in appetite regulation and energy expenditure.
FTO has significant connections to obesity and Type 2 diabetes. Genetic variants within the FTO gene correlate with risk for these conditions linking its enzymatic activity to alterations in energy balance and insulin sensitivity. FTO's role in Type 2 diabetes also highlights its interaction with insulin signaling proteins demonstrating its broader influence on glucose metabolism.
We have tested this species and application combination and it works. It is covered by our product promise.
We have not tested this specific species and application combination in-house, but expect it will work. It is covered by our product promise.
This species and application combination has not been tested, but we predict it will work based on strong homology. However, this combination is not covered by our product promise.
We do not recommend this combination. It is not covered by our product promise.
We are dedicated to supporting your work with high quality reagents and we are here for you every step of the way should you need us.
In the unlikely event of one of our products not working as expected, you are covered by our product promise.
Full details and terms and conditions can be found here:
Terms & Conditions.
Overlay histogram showing SH-SY5Y cells stained with ab92821 (red line). The cells were fixed with 80% methanol (5 min) and then permeabilized with 0.1% PBS-Tween for 20 min. The cells were then incubated in 1x PBS / 10% normal goat serum / 0.3M glycine to block non-specific protein-protein interactions followed by the antibody (ab92821, 1µg/1x106 cells) for 30 min at 22ºC. The secondary antibody used was DyLight® 488 goat anti-mouse IgG (H+L) (Goat Anti-Mouse IgG H&L (DyLight® 488) preadsorbed ab96879) at 1/500 dilution for 30 min at 22ºC. Isotype control antibody (black line) was mouse IgG2a [ICIGG2A] (Mouse IgG2a, Kappa Monoclonal [B12/8] - Isotype Control ab91361, 1µg/1x106 cells) used under the same conditions. Acquisition of >5,000 events was performed. This antibody gave a positive signal in SH-SY5Y cells fixed with 4% paraformaldehyde (10 min)/permeabilized with 0.1% PBS-Tween for 20 min used under the same conditions.
Lanes 1 - 4: Merged signal (red and green). Green - ab92821 observed at 58 kDa. Red - loading control, Anti-GAPDH antibody [EPR16891] - Loading Control ab181602, observed at 37 kDa.
ab92821 was shown to specifically recognize FTO in wild-type HAP1 cells along with additional cross reactive bands. No band was observed when FTO knockout samples were examined. Wild-type and FTO knockout samples were subjected to SDS-PAGE. ab92821 and Anti-GAPDH antibody [EPR16891] - Loading Control ab181602 (Rabbit anti-GAPDH loading control) were incubated overnight at 4°C at a 1/1000 dilution and 1/10,000 dilution respectively. Blots were developed with Goat anti-Mouse IgG H&L (IRDye® 800CW) preabsorbed (Goat anti-Mouse IgG H&L (IRDye® 800CW) preadsorbed ab216772) and Goat anti-Rabbit IgG H&L (IRDye® 680RD) preabsorbed (Goat Anti-Rabbit IgG H&L (IRDye® 680RD) preadsorbed ab216777) secondary antibodies at 1/10,000 dilution for 1 hour at room temperature before imaging.
All lanes: Western blot - Anti-FTO antibody [5-2H10] (ab92821)
Predicted band size: 58 kDa
All lanes: Western blot - Anti-FTO antibody [5-2H10] (ab92821) at 1/1000 dilution
All lanes: Rat testes lysate
Predicted band size: 58 kDa
Observed band size: 58 kDa
Please note: All products are 'FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES'.
For licensing inquiries, please contact partnerships@abcam.com